Quote:Here is a link to the MGK post that Midnight Rider suggested everyone read.
https://www.reddit.com/r/Livimmune/comments/1r8b1ni/arrival/
Here are the Cliff Notes:
The post argues that a new abstract by Dr. Richard Pestell and colleagues marks a major mechanistic validation for Leronlimab. According to the author, the data show that CCR5 blockade not only increases PD-L1 expression on tumor cells—potentially improving responsiveness to immune checkpoint inhibitors—but also reverses T-cell exhaustion by reducing markers like LAG3, TIM3, and CTLA4. In addition, Leronlimab appears to reduce immunosuppressive soluble factors such as sB7H3 and sTyro3, which are associated with immune resistance and tumor protection. Together, these effects are framed as a “Prime & Pair” strategy: first reactivating the immune environment, then enhancing the effectiveness of PD-1/PD-L1 blockade therapy.
The post connects these mechanistic findings to a planned Expanded Access Program launch and highlights a retrospective survival signal in heavily pre-treated metastatic triple-negative breast cancer patients (5 of 28 alive beyond 60 months). The author interprets this combination of biomarker shifts and survival data as evidence that Leronlimab may sensitize resistant tumors to immunotherapy, while commenters express optimism about upcoming colorectal cancer trial results and the drug’s tolerability. Overall, the tone is highly bullish, presenting the abstract as a turning point from theoretical promise to measurable biological and clinical impact.
16
CytoDyn Inc (CYDY) Stock Research Links
My comments are just my opinions and should NOT be taken as investment advice.
